東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Polyglutamine disorders

Nobrega, Clevio.

FindBook

Google Book

Amazon

博客來

Polyglutamine disorders

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Polyglutamine disorders/ edited by Clevio Nobrega, Luis Pereira de Almeida.
其他作者:	Nobrega, Clevio.
出版者:	Cham :Springer International Publishing : : 2018.,
面頁冊數:	viii, 469 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer eBooks
標題:	Nervous system - Diseases -
電子資源:	http://dx.doi.org/10.1007/978-3-319-71779-1
ISBN:	9783319717791

Polyglutamine disorders
Polyglutamine disorders[electronic resource] /edited by Clevio Nobrega, Luis Pereira de Almeida. - Cham :Springer International Publishing :2018. - viii, 469 p. :ill. (some col.), digital ;24 cm. - Advances in experimental medicine and biology,v.10490065-2598 ;. - Advances in experimental medicine and biology ;v.1049..

This book provides a cutting-edge review of polyglutamine disorders. It primarily focuses on two main aspects: (1) the mechanisms underlying the pathologies' development and progression, and (2) the therapeutic strategies that are currently being explored to stop or delay disease progression. Polyglutamine (polyQ) disorders are a group of inherited neurodegenerative diseases with a fatal outcome that are caused by an abnormal expansion of a coding trinucleotide repeat (CAG), which is then translated in an abnormal protein with an elongated glutamine tract (Q) To date, nine polyQ disorders have been identified and described: dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease (HD); spinal-bulbar muscular atrophy (SBMA); and six spinocerebellar ataxias (SCA 1, 2, 3, 6, 7, and 17) The genetic basis of polyQ disorders is well established and described, and despite important advances that have opened up the possibility of generating genetic models of the disease, the mechanisms that cause neuronal degeneration are still largely unknown and there is currently no treatment available for these disorders. Further, it is believed that the different polyQ may share some mechanisms and pathways contributing to neurodegeneration and disease progression.

ISBN: 9783319717791

Standard No.: 10.1007/978-3-319-71779-1doiSubjects--Topical Terms:

682330
Nervous system
--Diseases

LC Class. No.: RC346.4

Dewey Class. No.: 616.8

Polyglutamine disorders
LDR:02293nmm a2200313 a 4500 001 2133732
003 DE-He213
005 20180821135311.0
006 m d
007 cr nn 008maaau
008 181005s2018 gw s 0 eng d
020 $a 9783319717791 $q (electronic bk.)
020 $a 9783319717784 $q (paper)
024 7 $a 10.1007/978-3-319-71779-1 $2 doi
035 $a 978-3-319-71779-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC346.4
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
082 0 4 $a 616.8 $2 23
090 $a RC346.4 $b .P782 2018
245 0 0 $a Polyglutamine disorders $h [electronic resource] / $c edited by Clevio Nobrega, Luis Pereira de Almeida.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a viii, 469 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.1049
520 $a This book provides a cutting-edge review of polyglutamine disorders. It primarily focuses on two main aspects: (1) the mechanisms underlying the pathologies' development and progression, and (2) the therapeutic strategies that are currently being explored to stop or delay disease progression. Polyglutamine (polyQ) disorders are a group of inherited neurodegenerative diseases with a fatal outcome that are caused by an abnormal expansion of a coding trinucleotide repeat (CAG), which is then translated in an abnormal protein with an elongated glutamine tract (Q) To date, nine polyQ disorders have been identified and described: dentatorubral-pallidoluysian atrophy (DRPLA); Huntington's disease (HD); spinal-bulbar muscular atrophy (SBMA); and six spinocerebellar ataxias (SCA 1, 2, 3, 6, 7, and 17) The genetic basis of polyQ disorders is well established and described, and despite important advances that have opened up the possibility of generating genetic models of the disease, the mechanisms that cause neuronal degeneration are still largely unknown and there is currently no treatment available for these disorders. Further, it is believed that the different polyQ may share some mechanisms and pathways contributing to neurodegeneration and disease progression.
650 0 $a Nervous system $x Diseases $x Genetic aspects. $3 682330
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Neurosciences. $3 588700
650 2 4 $a Neurology. $3 588698
650 2 4 $a Gene Function. $3 1067308
700 1 $a Nobrega, Clevio. $3 2114871
700 1 $a Pereira de Almeida, Luis. $3 3301503
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v v.1049. $3 3301504
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-71779-1
950 $a Biomedical and Life Sciences (Springer-11642)